CompletedPhase 2NCT03664960

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Studying Eosinophilic gastroenteritis

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Allakos Inc.
Principal Investigator: Craig Paterson, MD, L. Ac
Allakos Inc.
Intervention: AK002(drug)
Enrollment: 58 enrolled
Eligibility: 18-80 years · All sexes
Timeline: 2018 – 2021

Study locations (17)

Phoenician Centers for Research and Innovation, Phoenix, Arizona, United States
Mayo Clinic Arizona, Scottsdale, Arizona, United States
Ventura Clinical Trials, Ventura, California, United States
Advanced Research Institute, New Port Richey, Florida, United States
Northwestern, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
NIH, Bethesda, Maryland, United States
Tufts Medical Center, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
Mount Sinai, New York, New York, United States
University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
ClinSearch, Chattanooga, Tennessee, United States
Vanderbilt University, Nashville, Tennessee, United States
+2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03664960 on ClinicalTrials.gov

Other trials for Eosinophilic gastroenteritis

Additional recruiting or active studies for the same condition.

See all trials for Eosinophilic gastroenteritis →

← Back to all trials